CG oncology, Inc. (CGON)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
$63.47-0.77%
Close 2026-10-29 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put CGON beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Biotechnology is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRanks in the weakest quality tier of its industry — roughly the bottom 40%, softest on free-cash-flow margins.
View QualityMiddle-of-the-pack management execution.
View ManagementThis stock is volatile — it swings about 2% on a typical day and fell roughly 27% in its worst 12-month stretch.
View RiskCGON’s case rests on its stated management commitment, but management is behind. Revenue growth cannot be assessed from the available earnings history. The company reported a GAAP loss per share in Q2 FY2026. The latest surprise missed by 28.6%. No valuation multiple or peer comparison is available in the desk. Our model puts next-quarter miss probability at 68%. Management’s delay on its commitment threatens the thesis. The thesis is on watch; this read is provisional.
Trailing returns as of 2026-10-29. CGON is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 15 analysts currently covering CGON (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare CGON with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CGON Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 0 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Biotechnology — fair value, gap to price, and forward P/E.
Compare the value case
Put CGON next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Advance Phase 2 CORE-008 clinical trial results
Cretostimogene readout is crucial for Phase 2 trial progress.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Above average on quality vs scored peers
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
Phase 3 data indicates significant progress in bladder cancer treatment.
BLA progress is crucial for regulatory approval.
Leadership consolidation may enhance commercialization efforts.
Positive analyst rating supports valuation outlook.
Increased price target reflects positive data impact.